2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu123PMID 24669016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.

  2015cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013influential reference
• Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  2013cited by this paper
• Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

  2013cited by this paper
• Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

  2013cited by this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cited by this paper
• Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

  2013cited by this paper
• Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

  2013cited by this paper
• Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

  2013cited by this paper
• Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

  2013cited by this paper
• Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

  2012cited by this paper
• Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

  2012cited by this paper
• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012influential reference
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations

  2012cited by this paper
• Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

  2012cited by this paper
• Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

  2012cited by this paper
• Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial

  2012cited by this paper
• Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives

  2012cited by this paper
• Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

  2011cited by this paper
• Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

  2011influential reference
• Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

  2011influential reference
• Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.

  2011cited by this paper
• Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

  2010influential reference
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

  2010cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

  2009cited by this paper
• Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

  2009cited by this paper
• Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice

  2009cited by this paper
• Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

  2009cited by this paper
• Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

  2009cited by this paper
• Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

  2008cited by this paper
• Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.

  2008cited by this paper
• Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

  2008cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005influential reference
• Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

  2004cited by this paper
• Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

  2003cited by this paper
• Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

  2003cited by this paper
• Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

  2001influential reference
• Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

  2001cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

  1999cited by this paper

• Prediction of solitary ≤3-cm small adrenal metastasis based on 18F-FDG PET/CT using a support vector machine model in lung cancer

  2025cites this paper
• The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer.

  2025cites this paper
• A monocentric retrospective analysis of 10-year overall survival after stereotactic body radiotherapy for medically inoperable non-small cell lung cancer

  2025cites this paper
• Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancer

  2025cites this paper
• Role of nanomedicines in lung cancer treatment and diagnosis: opportunities and challenges

  2025cites this paper
• A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience

  2024cites this paper
• Recent advances in albumin nanoparticle-based cancer therapies

  2024cites this paper
• Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy

  2024cites this paper
• Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

  2024cites this paper
• Genetic profiles of oligometastatic non-small-cell lung cancer and corresponding brain metastases

  2024cites this paper
• Targeting hyaluronan metabolism-related molecules associated with resistant tumor-initiating cells potentiates chemotherapy efficacy in lung cancer

  2024cites this paper
• Prognostic thresholds of FDG-PET SUVmean and SUVmax for survival and nodal involvement in lung neuroendocrine neoplasms.

  2024cites this paper
• Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study

  2024cites this paper
• The Detailed Analysis of Polish Patients with Non-Small Cell Lung Cancer Through Insights from Molecular Testing (POL-MOL Study)

  2024cites this paper
• Combined use of radiotherapy and tyrosine kinase inhibitors in the management of metastatic non-small cell lung cancer: a literature review.

  2024cites this paper
• Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

  2024cites this paper
• Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy

  2023cites this paper
• Refusal of Subsequent Treatment in Patients With EGFR-mutant Non-small-cell Lung Cancer After Response to EGFR-TKIs.

  2023cites this paper
• Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

  2023cites this paper
• Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis

  2023cites this paper
• Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

  2023cites this paper
• Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis

  2023cites this paper
• Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

  2023cites this paper
• Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

  2023cites this paper
• Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China

  2023cites this paper
• Non – Small Cell Lung Cancer, Version 3.2022

  2022cites this paper
• Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.

  2022cites this paper
• Ranking the most influential predictors of CT-based radiomics feature values in metastatic lung adenocarcinoma.

  2022cites this paper
• BPIFB2 is highly expressed in "cold" lung adenocarcinoma and decreases T cell chemotaxis via activation of the STAT3 pathway.

  2022cites this paper
• Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective

  2022cites this paper
• Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer

  2022cites this paper
• Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review

  2022cites this paper
• Body Weight Change in Non-small Cell Lung Cancer Patients Treated With EGFR-TKI.

  2022cites this paper
• A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT)

  2022cites this paper
• Non-Small Cell Lung Cancer Presenting as a Mobile Left Atrial Mass

  2022cites this paper
• Analyses of P16^INK4a gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: A pilot study

  2022cites this paper
• Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study

  2022cites this paper
• Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.

  2022cites this paper
• Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

  2022cites this paper
• Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cites this paper
• Systemic Anti-Cancer Therapy Patterns in Advanced Non-Small Cell Lung Cancer in Europe.

  2022cites this paper
• Patient and Clinician Preferences for Genetic and Genomic Testing in Non-Small Cell Lung Cancer: A Discrete Choice Experiment

  2022cites this paper
• Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer

  2021cites this paper
• A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

  2021cites this paper
• Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma

  2021influential citation
• Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

  2021cites this paper
• American Radium Society™ Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.

  2021cites this paper
• An international field study to investigate the psychometric properties of the updated EORTC QLQ-LC29 module for assessing quality of life in patients with lung cancer

  2021cites this paper
• Clinical-pathological challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice.

  2021influential citation
• Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.

  2021cites this paper
• Application of endobronchial ultrasound-guided transbronchial needle aspiration for re-biopsy in lung cancer

  2021cites this paper
• Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

  2021cites this paper
• Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis

  2021cites this paper
• Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

  2021cites this paper
• Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial

  2021cites this paper
• Clinical Significance of a Circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma

  2021cites this paper
• A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells

  2021cites this paper
• Combined High-Dose LATTICE Radiation Therapy and Immune Checkpoint Blockade for Advanced Bulky Tumors: The Concept and a Case Report

  2021cites this paper
• Prognostic Model to Predict Overall Survival for Metastatic Non-Small Cell Lung Cancer Patients Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Analysis From Two Prospective Studies

  2021cites this paper
• The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

  2021cites this paper
• Japanese Lung Cancer Society Guideline for stage IV non-small cell lung cancer with epidermal growth factor receptor mutations

  2021cites this paper
• Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

  2021cites this paper
• The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance

  2021cites this paper
• Activation of anti-oxidant Keap1/Nrf2 pathway modulates efficacy of dihydroartemisinin-based monotherapy and combinatory therapy with ionizing radiation.

  2021cites this paper
• KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)

  2021cites this paper
• SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

  2020cites this paper
• Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study

  2020cites this paper
• Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.

  2020cites this paper
• Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

  2020cites this paper
• Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece

  2020cites this paper
• The Clinical Impact of Re-biopsies in Lung Adenocarcinoma: a Retrospective Multicenter Study

  2020cites this paper
• Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer

  2020cites this paper
• Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323

  2020cites this paper
• A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

  2020cites this paper
• Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.

  2020cites this paper
• Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients

  2020cites this paper
• Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.

  2020cites this paper
• Radiotherapy Planning and Molecular Imaging in Lung Cancer

  2020cites this paper
• Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.

  2020cites this paper
• Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

  2020cites this paper
• Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer.

  2020cites this paper
• Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer

  2020cites this paper
• Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy

  2020cites this paper
• Cost-effectiveness analysis of osimertinib for first-line treatment of locally 3 advanced or metastatic EGFR mutation positive non-small cell lung cancer

  2020cites this paper
• Association between the Khorana score and pulmonary embolism risk in patients with advanced stage lung cancer

  2020cites this paper
• Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

  2020cites this paper
• Long-Term Quality of Life in Operated Non-Small Cell Lung Cancer Patients

  2020cites this paper
• Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias

  2020cites this paper
• Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines.

  2020cites this paper
• Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

  2020cites this paper
• 2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology

  2020cites this paper
• MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial–mesenchymal transition by targeting twinfilin actin binding protein 1

  2019cites this paper
• Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study

  2019cites this paper
• Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing

  2019cites this paper
• CMAR_A_219722 10239..10248

  2019cites this paper
• Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment

  2019cites this paper
• Early mortality of stage IV non-small cell lung cancer in the United States

  2019cites this paper
• AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany

  2019cites this paper
• SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic–smoking interaction analysis

  2019cites this paper
• Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer

  2019cites this paper